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Objective: To evaluate immunogenicity and tolerability of
single dose live attenuated injectable hepatitis A vaccine in
four metropolitan cities of India.
Methods: Live attenuated hepatitis A vaccine was
administered to 505 children aged 18 - 60 months in four
centers across India. Immunogenicity of the vaccine was
assessed by estimation of anti-HAV antibody titer at 6
weeks and 6 months following administration of the
vaccine. Safety evaluation of the vaccine was also done
during the visits.
Results: At 6 weeks, 480 subjects (95%) came for the
follow-up and 411 (81.4%) subjects reported at the end of 6
months. The geometric mean titer (GMT) of anti-HAV
antibody of the subjects who did not have the
seroprotective titer at the baseline were assessed at 6
weeks and 6 months which was 81.04 mIU/ml and 150.66
mIU/ml respectively. At 6 weeks, 95.1 % seroconverted
and at the end of 6 months, 97.9 % had seroconverted.
Both solicited and unsolicited vaccine-induced local
and systemic adverse events were insignificant at
all the centers, except swelling and induration
in a few.
Conclusion: Live attenuated injectable hepatitis A
vaccine was immunogenic and tolerable with minimal
reactogenecity, in this study of single dose schedule.
Safety profile was also satisfactory in the study population.
Keywords: Hepatitis A vaccine, Immunogenicity, Live
attenuated, Safety, Single dose.
Hepatitis A virus (HAV) infection iscommon throughout the developingworld and is frequently acquired duringearly childhood. Though HAV
commonly affects children but adolescent and adults
are also at risk in India. Countries in transition from
developing to developed economies are likely
witness a shift in disease prevalence from high to
intermediate endemicity, and HAV is likely to
become a more serious problem in these areas. The
aftermath of this changing endemicity pattern will
alter the incidence of the morbidity and mortality of
the disease and make the adolescent and adult
population more vulnerable.
In India, seroprevalence ranged from 32% to
80% in children younger than 10 years age in
different demographic profile(1-3). Report of an
explosive outbreak of hepatitis A involving 1180
adult cases from Kerala provides an example of
R E S E A R C H P A P E R
INDIAN  PEDIATRICS 30 VOLUME 46__JANUARY 17, 2009
FARIDI, et al. LIVE ATTENUATED HEPATITIS A VACCINE
epidemic potential of HAV in India with respect to
the changing epidemiology(4).
In this changing scenario, WHO has
recommended large scale hepatitis A vaccination
programs in areas which are prone for epidemic
outbreaks. Two types of HAV vaccines are now
available in the market, namely, inactivated vaccine
and live attenuated vaccine. Two doses are
recommended at an interval of 6–12 months in the
inactivated vaccine(5), but in case of live attenuated
vaccine only a single dose is recommended by the
inventor and the manufacturer in the country of
origin (China). WHO has encouraged studies
addressing the duration of protection following a
single dose of the vaccine(6).
In India, the first study on hepatitis A live
attenuated vaccine was undertaken at Pune, in which
the vaccine was shown to be immunogenic(7). The
present multicentric study was carried out in Delhi,
Mumbai, Kolkata and Chennai to measure
immunogenicity, safety and geometric mean titers of
the anti-HAV antibodies up to 6 months following
immunization with a live attenuated hepatitis A
vaccine.
METHODS
A prospective, multicentric, open labeled hospital
based study was conducted at the four metropolitan
cities of India, namely Delhi, Mumbai, Kolkata and
Chennai from April 2007 to February 2008 amongst
505 subjects. Estimating higher prevalence of
seropositivity in the older age group, the age wise
sample distribution was 75% below 4 years and 25%
above 4 years. The study was initiated at each center
after obtaining approval of the study protocol from
the ethical committee of the respective institution
and the study was conducted in accordance with
ICMR guidelines for biomedical research on human
subjects and the Declaration of Helsinki. Subject
recruitment was commenced only after explaining
the matter in the informed consent form printed in
local language and was signed by the parents/
guardian of the child.
After enrolling the subjects, the present and past
medical history, the demographic and socio-
economic profile of the study subjects were
transcribed on to the case record forms. Clinical
examination was conducted and blood samples were
drawn at the baseline for complete blood count,
serum bilirubin levels, liver enzymes and anti- HAV
antibody estimation. All biochemical, hematological
and serological test were conducted at SRL Ranbaxy
Laboratory, Mumbai.
The freeze-dried live attenuated hepatitis A
vaccine (H2 strain) developed by Zhejiang Pukang
Biotechnological Company Ltd., China was used in
the study. Live attenuated hepatitis A vaccine was
shipped and stored at temperatures ranging from
35.6ºF (2ºC) to 46.4ºF (8ºC). The vaccine was
reconstituted immediately before vaccination and
injected subcutaneously in the deltoid region.
Immunogenecity of the vaccine was assessed by
estimation of anti-HAV antibody titer at 6 weeks and
6 months following administration of the single dose
of the vaccine. After vaccination the child was
observed in the immunization clinic of respective
centres for one hour to watch for immediate adverse
vaccine reaction. The parents were advised to report
to the hospital for any untoward incidence and to
keep a record of fever, local pain, erythema and
induration at the site of vaccination. Further safety
evaluation was done by clinical examination and
comparison of any changes from the baseline of liver
enzyme and complete blood count (CBC) at 6 weeks
following vaccination.
The method used for the quantitative estimation
of HAV antibody in this study was Axsym® -
HAVAB 2.0 Quantitative assay, based on the
principle of Microparticle Enzyme Immunoassay
(MEIA), on the kit Abbott Axsym. Although an
immune level for anti-HAV antibodies has not been
established(8), results of previous studies have
suggested that values of approximately 10 mIU/
mL(9) to 20mIU/mL(10) may be indicative of
immunity. Invitro studies using cell-culture-derived
virus indicate that low levels of antibody (e.g., less
than 20 mIU/mL) can be neutralizing(11). HAV
vaccine responders were defined as those subjects
who converted from an initially seronegative to a
seropositive status using the different cut-off levels,
10 to 20mIU/ml as seroprotective. For comparison of
geometric mean values and 95% Confidence
Intervals (CIs), and comparisons over different
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age-groups, Students’ t-test was used for parametric
data. All analyses were 2-tailed with P=0.05 as the
cut off level for statistical significance. SPSS for
Windows version 11.0 (Illinois, Chicago: SPSS Inc.,
2002) software was used for statistical analysis.
RESULTS
Five hundred and five subjects in the age group of 18
to 60 months were enrolled in all the four centres
irrespective of their baseline seroprevalence status.
Demographic data like location, age, sex and
drinking water supply, sanitary and socioeconomic
conditions were recorded. Of the total 505 subjects
enrolled in the study, 480(95%) subjects came for
follow up at 6 weeks and 411 (81.4%) subjects
reported at the end of 6 months. Serum specimen was
collected during each visit to estimate anti-HAV
antibodies along with complete blood counts and
liver enzymes. Due to inadequate quantity of serum
sample during baseline estimation, two subjects
were excluded from the study subsequently.
The seroprevalence of anti-HAV antibodies
before vaccination is shown in Table I. It was seen
that the seroprevalence at baseline was 33% across
all age groups (21% in children <2 years old, 30% in
those 2 to 4 years of age, and 38% in those >4 years
of age). Seroprevalence also varied in different cities
and was lowest in Chennai, around 18% only.
The anti-HAV antibody geometric mean titer
(GMT) was assessed at 6 weeks and 6 months for the
baseline seronegative subjects only, after single dose
of the live attenuated HA vaccine. Table II shows the
seroconversion after 6 weeks following single dose
of hepatitis A vaccine according to different
seroprotective cut-off levels of antibody
concentrations, which ranged from 95% to 98%.
The variation in the HAV titer values in the
subsequent visits, i.e., in the first and the second
visits after the baseline visit can be best studied if the
interquartile range rather than simple range or
variance is taken, because the effect of extreme
observations and outliers can be eliminated by this
process. The values found in the first and the second
visits were 54.52 (first quartile=45.48, third quartile
=100.00) and 101.00 (first quartile=92.25, third
quartile=193.25) respectively. The subjects included
were only those who were seronegative at the
baseline (<20 mIU/mL) and attained an antibody
concentration of >20mIU/mL after 6 weeks and 6
months. The age-wise seroconversion at 6 weeks and
6 months following single dose administration of
live attenuated hepatitis A vaccine is shown in Table
III. There were two non-responders in Mumbai and
one in Kolkata, whose antibody concentration did
not rise following vaccination.
There was no significant change in serum
bilirubin and ALT values at baseline and after 6
weeks. In 1.8% cases, there was marginal rise of the
enzyme which clinically was not significant as
neither there was rise in the bilirubin level nor any
suggested history of clinical jaundice. In the 6 weeks
follow-up visit, 1.2% of the cases had raised alanine
aminotransferase level but the bilirubin level was
normal in all of them and none had any history of
clinical hepatitis. Rest of the hematological reports
was within normal limits both at the baseline and
after 6 weeks of the vaccination.
TABLE I HAV SEROPREVALENCE AT BASELINE IN CHILDREN ACROSS 18 – 60 MONTHS AGE
Anti-HAV 18-24 months 25-36 months  37-48 months  49-60 months
Antibody (n=75) (n=179) (n=123) (n=126)
Titer No. % No. % No. % No. %
0.00–0.99 40 53.33 66 36.87 43 34.95 39 30.95
1.00–4.99 15 20.00 54 30.16 40 32.52 37 29.36
5.00–9.99 2 2.66 4 2.23 1 1.62 2 1.58
10.00–14.99 1 1.33 0 0 1 0.81 0 0
15.00–9.99 1 1.33 3 1.67 0 0 0 0
>20.00 16 21.33 52 29.05 38 30.89 48 38.09
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TABLE II IMMUNOGENICITY OF LIVE ATTENUATED HEPATITIS A VACCINE IN CHILDREN CONSIDERING DIFFERENT
SEROPROTECTIVE CUT-OFF VALUES FOR ANTI- HAV ANTIBODY TITERS
Anti-HAV antibody Percentage Post Vaccination antibody titers GMT
cut-off titers for Seroconversion  ( 95 % C.I.)
seroprotection
(mIU/mL) 6 weeks 6 months 6 weeks 6 months
≥H10 98.1 99.3 78.18(68.10-89.75) 144.46 (127.61-163.53)
≥H15 97.8 99.3 78.02(68.03-89.48) 143.88 (127.23-162.88)
≥H20 95.1 97.9 81.04(70.67-92.85) 150.66 (133.09-170.37)
Percentage serconversion has been calculated by the number of subjects who did not have the seroprotective titer at the
baseline with the number of subjects who finally attained seroprotective antibody titer (different cut-off levels) after vaccination
at 6 weeks and 6 months follow-up visit.
TABLE III AGE-WISE SEROCONVERSION* AT 6 WEEKS FOLLOWING SINGLE DOSE ADMINISTRATION OF LIVE ATTENUATED
HEPATITIS A VACCINE
At 6 weeks following vaccination At 6 months following vaccination
Age n1 (%) GMT 95% CI n2 (%) GMT 95% CI
(months) (mIU/mL) LL UL (mIU/mL) LL UL
18 – 24 57 98.28 108.42 76.02 154.47 49 100.00 195.20 147.08 259.30
25 – 36 115 97.46  91.65 70.18 119.70 108 99.08 161.10 128.77 201.54
37 – 48 78 98.73  58.09 46.62  72.46 67 100.00 112.06 89.75 139.91
49 – 60 66 97.06  62.99 50.70  78.26 55 98.21 119.34 93.22  152.62
Total 316 97.89 78.02 68.03  89.48 279 99.29 143.88 127.23 162.88
n1 = number of cases at first follow up at 6 weeks. n2 = number of cases at second follow visit
*Seroconversion: subjects who did not have the seroprotective titer at baseline prior to vaccination and attained seroprotective
titer after vaccination at 6 weeks and 6 months
Both solicited and unsolicited vaccine-induced
local and systemic adverse events were insignificant
at all the centers, except mild swelling and slight
induration in a few children. The incidence of
solicited adverse events varied from 0.20 to 1.85%
and the unsolicited adverse events ranged from 0.20
to 0.82%. One subject from Kolkata centre
developed systemic panniculitis which was not
related to the vaccine as per the opinion of the
dermatologist, and it subsequently subsided and the
patient came for the follow-up visit at 6 months.
There were no withdrawals from any centre on
account of adverse events.
DISCUSSION
The study revealed that the administration of the live
attenuated hepatitis A vaccine was found to be highly
immunogenic with good tolerability and minimal
reactogenecity in children 18 to 60 months of age.
The seroconversion ranged from 95% to 98% at 6
weeks and 98% to 99% at 6 months considering the
different cut-off levels of seroprotective antibody
titers. The geometric mean titer (GMT) of anti-HAV
antibody of the subjects who did not have the
seroprotective titer at the baseline were assessed at 6
weeks and 6 months, which was 81.04 mIU/mL
(95% CI–70.67-92.85 ) and 150.66 mIU/mL ( 95%
CI–127.23–162.88), respectively following the
vaccination when >20mIU/mL was considered as the
seroprotective titer.
The variation in the HAV titers in the
interquartile analysis revealed that the variation
increased as the time gap increased. The increasing
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anti-HAV antibody titers at 6 months following
single dose of the vaccine might be due to the fact
that this vaccine contained whole structure of the
attenuated H2 strain virus particle that induced
immune responses similar to the natural infection in
humans. Besides this, the increase in seroconversion
could be due to natural infection also. It has been
reported that this vaccine can induce not only
neutralizing antibodies but also the cell-mediated
immune responses. As a result, the protection based
on cellular immunity could persist even after anti-
HAV antibodies become undetectable. When
vaccinees are re-exposed to HAV, an anamnestic
response may well prevent overt disease(12).
While analysing the age-wise seroconversion at 6
weeks and 6 months following single dose
administration of the vaccine, the GMT at 6 weeks
and 6 months were maximum in the age group 18-24
months. Thus the vaccine is highly immunogenic at
an early age. In other groups, most of the subjects
achieved seroprotective level at 6 months following
single dose of the vaccine. More than 95% children
who did not report at 6 months had seroconverted at
6 weeks. The observations show that inclusion of
this group would not have changed the data
significantly with the inclusion in the final analysis.
In this study, 3 subjects were nonresponders,
which may be due to a lowered immunity in general
or because the host’s immune system did not have a
B-cell capable of generating antibodies against that
antigen. In a multivariate analysis, it has been seen
that the CD4 count at the time of vaccination was
associated with the absence in the response to
hepatitis A vaccine (P<0.0001)(13). In our study,
these subjects could not be followed up for the CD4
count.
We did not find serious vaccine related adverse
reaction in any subject over a period of 6 months
after administration of the vaccine. Excepting in few
cases, subjects developed mild swelling, pain and
erythema. None of the child developed clinical or
biochemical hepatitis following vaccination.
Although we observed the safety profile in the
subjects, this study was not adequately powered
statistically to comment on the safety of the vaccine
as the primary outcome.
The only Indian study(7) on this vaccine has
shown its high immunogenicity and excellent safety
profile that is further strengthened by the present
study. Studies from China also showed high
immunogenicity of the vaccine and the long term
studies showed persistence of protective antibody
level up to 15 years following a single dose of live
attenuated HA vaccine. A comparative study
with single and booster dose did not reveal any
significant advantage in the long term protective
value with the addition of booster(12,14-16).
Further studies to evaluate the long term persistence
of anti-HAV antibody after the single dose of live
attenuated hepatitis A vaccine in children of India,
are needed.
It can be concluded that this live attenuated
hepatitis A vaccine is tolerable with minimal
reactogenecity and it is immunogenic in children 18
months to 5 years of age with the single dose.
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WHAT IS ALREADY KNOWN?
• Single dose injectable live attenuated hepatitis A vaccine is immunogenic and safe in children 18-60 months
in only one center in India.
WHAT THIS STUDY ADDS?
• Single dose injectable live attenuated hepatitis A vaccine is immunogenic and safe in children 18 – 60 months
across different geographical areas in India.
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